A Phase 1 interventional study of Covid-19 vaccine and Influenza vaccine in covid19 Infection and Influenza, Human, sponsored by Vaxine Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Vaxine Pty Ltd · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in COVID-19 with a site in Australia — 6 open to participants now, 15 under way, 8 of them phase 3. COVID-19 · Australia.
Among the 89 studies in COVID-19 with a site in Australia, this one is the 46th largest by planned enrollment of the 79 interventional ones that give a count, is one of 6 that started in 2024, is one of 28 in phase 1, reaches primary completion later than 7 of the 14 other live ones, and was the 85th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 89 studies in COVID-19 with a site in Australia are open now. Recruiting first, the newest first:
Kirby Institute · Sites in Australia
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 36 more countries
Ages 18+
University of Adelaide · Sites in Australia
Ages 6 mo+
Ansun Biopharma, Inc. · Sites in Australia, United States, China and 2 more countries
UMC Utrecht · Sites in Australia, United States, Belgium and 26 more countries
Ages 28 days+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 18 · Phase 3 29 · Phase 4 3
First in 2016; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 185 across the 79 interventional studies, 1,000 across the 9 observational. Of the 63 that completed or were terminated, 17 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 89 have an industry lead sponsor. The 10 most frequent:
Vaxine Pty Ltd is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Vaxine Pty Ltd has 5 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05415267Phase 3Kirby InstituteImmunosuppression and COVID-19 Boosters | 2026-12-31 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 89 studies in COVID-19 with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.
The SARS-CoV-2 outbreak has caused millions of deaths globally. It has a particularly high mortality rate in elderly people and those with chronic disease. SARS-COV-2 vaccines remain a key priority to help fight the current pandemic as they help reduce symptomatic infection and disease severity. However, vaccine immunity starts to wane as early as 3 months following the most recent immunisation. This rapidly waning vaccine immunity is a particular problem for the newer Omicron variants. Spikogen® vaccine is an Advax-CpG55.2 adjuvanted recombinant protein vaccine that was shown to significantly reduce infection and serious disease in a pivotal Phase 3 trial in 16,876 participants who received two intramuscular doses 3 weeks apart. SpikoGen® vaccine was licensed for use in the Middle East as a primary vaccine course in adults in October 2021. Eight million doses of SpikoGen® vaccine have subsequently been supplied to date. A booster study confirmed the safety and immunogenicity of SpikoGen® vaccine when given as a third dose intramuscular booster to adult participants who previously received two doses of either inactivated viral vaccine, adenoviral vector vaccine, mRNA or recombinant protein vaccine. While COVID-19 vaccines such as SpikoGen® vaccine have been shown to reduce the incidence of severe SARS-CoV-2 infection disease, they have less effect on SARS-CoV-2 infection or transmission. This is because intramuscular vaccines largely work by increasing antibody and T cell levels within the body, whereas what is needed to prevent infection and transmission is mucosal immunity, which means increasing immunity at the body surfaces where the virus initially gets access to the body, namely the mucosal surfaces of the nose and upper respiratory tract. To induce mucosal immunity normally requires immune cells at these respiratory tract surfaces to be exposed to the relevant viral antigen, which requires the vaccine to be applied to these surfaces in such a way as to trigger an appropriate immune response.The current study is based on the finding that an adjuvanted protein-based COVID-19 vaccine (SpikoGen®) when given as 2 sublingual doses 2 weeks apart in monkeys that had previously received a primary course of 2 intramuscular doses of the same vaccine, was safe and well tolerated and induced robust protection against challenge with the heterologous Omicron BA.5 virus. The monkeys that received the sublingual boost also showed reduced nasal virus shedding (additional details in the Investigator Brochure). This suggests an oral/ sublingual COVID-19 vaccine may also help block virus transmission. Similarly, mice that received sublingual inactivated influenza vaccine with Advax-CpG adjuvant have demonstrated robust protection against an otherwise lethal influenza infection. The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group will receive two sublingual doses of COVID-19 vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of influenza vaccine two weeks apart.
Biological: Covid-19 vaccine · Biological: Influenza vaccine
Subjects in this group will receive two sublingual doses of influenza vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of COVID-19 vaccine two weeks apart.
Biological: Covid-19 vaccine · Biological: Influenza vaccine
Subjects in this group will receive two sublingual doses of combined COVID-19 and influenza vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of placebo vaccine two weeks apart.
Biological: Covid-19 vaccine · Biological: Influenza vaccine
Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant
Also known as: SARS-CoV-2 vaccine
Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant
SARS-CoV-2 Seroconversion
Proportion of study participants who seroconvert (4-fold or greater rise in serum spike antibody) by primary vaccine group
Time frame: Between baseline and 2 weeks post the second dose
Influenza Seroconversion
Proportion of study participants who seroconvert (4-fold or greater rise in hemagglutinin antibody) by primary vaccine group
Time frame: Between baseline and 2 weeks post the second dose
SARS-CoV-2 Seroprotection
Proportion of study participants who achieve a spike protein neutralisation titer of 32 or greater by primary vaccine group
Time frame: Between baseline and 2 weeks post the second dose
Influenza Seroprotection
Proportion of study participants who achieve a hemagglutinin neutralisation titer of 40 or greater by primary vaccine group
Time frame: Between baseline and 2 weeks post the second dose
SARS-CoV-2 Geometric mean titer fold change
Increase in Geometric mean titer of spike neutralisation antibodies by primary vaccine group
Time frame: Between baseline and 2 weeks post the second dose
Influenza geometric mean titer fold change
Increase in Geometric mean titer of spike neutralisation antibodies by primary vaccine group
Time frame: Between baseline and 2 weeks post the second dose
Safety assessment 1
Frequency of Adverse events by primary vaccine group
Time frame: Between time of administration of first dose and through study completion, an average of 10 months
Safety assessment 2
Frequency of Serious Adverse events by primary vaccine group
Time frame: Between time of administration of first dose and through study completion, an average of 10 months
SARS-CoV-2 infection
Frequency of SARS-CoV-2 infections in study participants by primary vaccine group, age, gender, co-morbidities, and past infection
Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Influenza infection
Frequency ofinfluenza infections in study participants by primary vaccine group, age, gender, co-morbidities, and past infection
Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Antibody durability
The proportion of subjects who remain seroprotected throughout the duration of the study including broken down by primary vaccine group.
Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Seroconversion in participants with and without evidence of past infection
Antibody seroconversion in participants by primary vaccine group
Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Antibody GMT in participants with and without evidence of past infection
Antibody GMT in baseline seropositive versus negative participants by primary vaccine group.
Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Antibody correlates of protection
antibody levels in subjects with or without breakthrough infection
Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months
Plan to share: No — There is no plan to share IPD with external researchers
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 19 months is above that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vaxine Pty Ltd